Cargando…

Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum

OBJECTIVE: To investigate the expression and clinical significance of miR-146a and tumor necrosis factor receptor-associated factor 6 (TRAF6) in myasthenia gravis (MG) patient serum. METHODS: The serum of 52 patients with MG and 60 healthy individuals was collected in our hospital. The expression of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Mei, Fu, Yue, Rao, Hui, Zhou, Huiling, Liang, Xiaohuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081603/ https://www.ncbi.nlm.nih.gov/pubmed/33997016 http://dx.doi.org/10.1155/2021/5573469

Ejemplares similares

Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
por: Li, Ting, et al.
Publicado: (2022)

Regulation of MiR-146a and TRAF6 in the Diagnose of Lupus Nephritis
por: Zhu, Yunfeng, et al.
Publicado: (2017)

miR-146a Inhibits dengue-virus-induced autophagy by targeting TRAF6
por: Pu, Jieying, et al.
Publicado: (2017)

miR-146b-5p promotes colorectal cancer progression by targeting TRAF6
por: Shi, Liangpan, et al.
Publicado: (2022)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
por: Bortone, Federica, et al.
Publicado: (2020)

miR-146a Ameliorates Liver Ischemia/Reperfusion Injury by Suppressing IRAK1 and TRAF6
por: Jiang, Weiwei, et al.
Publicado: (2014)

miR-146a-5p Plays an Oncogenic Role in NSCLC via Suppression of TRAF6
por: Liu, Xiangdong, et al.
Publicado: (2020)

miR-146-5p restrains calcification of vascular smooth muscle cells by suppressing TRAF6
por: Yang, Jing, et al.
Publicado: (2022)

Correction: miR-146a Ameliorates Liver Ischemia/Reperfusion Injury by Suppressing IRAK1 and TRAF6
por: Jiang, Weiwei, et al.
Publicado: (2023)

miR-146a Enhances the Oncogenicity of Oral Carcinoma by Concomitant Targeting of the IRAK1, TRAF6 and NUMB Genes
por: Hung, Pei-Shi, et al.
Publicado: (2013)

MiR-146a down-regulates inflammatory response by targeting TLR3 and TRAF6 in Coxsackievirus B infection
por: Fei, Yanru, et al.
Publicado: (2020)

Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients
por: Nogales-Gadea, Gisela, et al.
Publicado: (2014)

miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas
por: Liu, Jing, et al.
Publicado: (2015)

Progressive Outer Retinal Necrosis and Immunosuppressive Therapy in Myasthenia Gravis
por: Coisy, Solène, et al.
Publicado: (2014)

Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis
por: Li, Yi, et al.
Publicado: (2019)

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
por: Maurer, Marie, et al.
Publicado: (2015)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Thymectomy lowers the myasthenia gravis biomarker miR-150-5p
por: Molin, Carl Johan, et al.
Publicado: (2018)

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019)

Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
por: Cron, Mélanie A., et al.
Publicado: (2020)

A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
por: Meng, Qingcai, et al.
Publicado: (2020)

Serum metabolomics of treatment response in myasthenia gravis
por: Sikorski, Patricia, et al.
Publicado: (2023)

miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice
por: Shi, Lei, et al.
Publicado: (2015)

Requirement of Tumor Necrosis Factor Receptor–Associated Factor (Traf)6 in Interleukin 17 Signal Transduction
por: Schwandner, Ralf, et al.
Publicado: (2000)

Serological diagnosis of myasthenia gravis and its clinical significance
por: Li, Yi, et al.
Publicado: (2019)

Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALP3 inflammasome
por: Zhang, Quan-Bo, et al.
Publicado: (2018)

MiR-146a Ameliorates Hemoglobin-Induced Microglial Inflammatory Response via TLR4/IRAK1/TRAF6 Associated Pathways
por: Liu, Guang-Jie, et al.
Publicado: (2020)

MiR-146b-5p/TRAF6 axis is essential for Ginkgo biloba L. extract GBE to attenuate LPS-induced neuroinflammation
por: Liu, Min, et al.
Publicado: (2022)

Extracellular vesicles derived from M1 macrophages deliver miR-146a-5p and miR-146b-5p to suppress trophoblast migration and invasion by targeting TRAF6 in recurrent spontaneous abortion
por: Ding, Jinli, et al.
Publicado: (2021)

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis
por: Tang, Mingbo, et al.
Publicado: (2023)

miR‐30e‐5p as predictor of generalization in ocular myasthenia gravis
por: Sabre, Liis, et al.
Publicado: (2019)

miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9
por: Wang, Qiang, et al.
Publicado: (2021)

P-1 Prognostic factors and course of myasthenia gravis
por: Albertini, E., et al.
Publicado: (2011)

B-Cell-Activating Factor and Autoimmune Myasthenia Gravis
por: Ragheb, Samia, et al.
Publicado: (2011)

Factors associated with poor outcomes of hospitalized myasthenia gravis
por: Tin, Sim S., et al.
Publicado: (2015)

Factors associated with quality of life of people with Myasthenia Gravis
por: Jeong, Ansuk, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3mi45rep4of1f67g5if6n39cab